📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Biophytis

1.1 - Company Overview

Biophytis Logo

Biophytis

Headquarter: France
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage therapeutics for metabolic and age-related diseases, developing orally administered small molecules including Ruvembri for sarcopenia via MAS receptor activation to stimulate respiratory and motor functions, BIO101 for neuromuscular diseases (sarcopenia, DMD) and in a phase 2 obesity study with GLP-1 receptor agonists, and Macuneos (BIO201) for retinal diseases (dry AMD, Stargardt).

Products and services

  • BIO101: A small molecule in development for neuromuscular diseases, including sarcopenia and Duchenne Muscular Dystrophy (DMD)
  • Ruvembri: An orally administered small molecule that activates the MAS receptor to stimulate respiratory and motor functions for sarcopenia treatment
  • Macuneos (BIO201): An orally administered small molecule for the treatment of retinal diseases, including dry Age-related Macular Degeneration (AMD) and Stargardt disease

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Biophytis

Cytovale Logo

Cytovale

HQ: United States Website
  • Description: Provider of early detection diagnostic technologies for immune-mediated diseases, including the IntelliSep Test for rapid sepsis identification with results in under 10 minutes to aid emergency department triage, powered by microfluidics, precision imaging, and machine learning to analyze complex biological data and perform detailed cellular analysis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cytovale company profile →
Trimeris Logo

Trimeris

HQ: United States Website
  • Description: Provider of HIV research and drug discovery, founded in 1993 in Morrisville, North Carolina, whose early work led to an entirely new class of anti-HIV drugs called fusion inhibitors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Trimeris company profile →
Visby Medical Logo

Visby Medical

HQ: United States Website
  • Description: Provider of instrument-free PCR diagnostic tests for infectious disease detection, including the single-use Sexual Health Test that detects Chlamydia, Gonorrhea, and Trichomoniasis from self-collected vaginal swabs in under 30 minutes, and the Respiratory Health Test that detects and differentiates COVID-19, Influenza A, and Influenza B via nasopharyngeal swabs in under 30 minutes.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Visby Medical company profile →
Tanomed Logo

Tanomed

HQ: Sweden Website
  • Description: Provider of medical product research and development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tanomed company profile →
Enantigen Logo

Enantigen

HQ: United States Website
  • Description: Provider of discovery, development, and commercialization of novel drugs for life-threatening infectious diseases, with a primary focus on oral therapeutics for the treatment of hepatitis; located at the Pennsylvania Biotechnology Center.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Enantigen company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Biophytis

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Biophytis

2.2 - Growth funds investing in similar companies to Biophytis

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Biophytis

4.2 - Public trading comparable groups for Biophytis

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Biophytis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Biophytis

What does Biophytis do?

Biophytis is a provider of clinical-stage therapeutics for metabolic and age-related diseases, developing orally administered small molecules including Ruvembri for sarcopenia via MAS receptor activation to stimulate respiratory and motor functions, BIO101 for neuromuscular diseases (sarcopenia, DMD) and in a phase 2 obesity study with GLP-1 receptor agonists, and Macuneos (BIO201) for retinal diseases (dry AMD, Stargardt).

Who are Biophytis's competitors?

Biophytis's competitors and similar companies include Cytovale, Trimeris, Visby Medical, Tanomed, and Enantigen.

Where is Biophytis headquartered?

Biophytis is headquartered in France.

How many employees does Biophytis have?

Biophytis has 1,000 employees 🔒.

When was Biophytis founded?

Biophytis was founded in 2010 🔒.

What sector and industry vertical is Biophytis in?

Biophytis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Biophytis

Who are the top strategic acquirers in Biophytis's sector and industry

Top strategic M&A buyers and acquirers in Biophytis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Biophytis?

Top strategic M&A buyers groups and sectors for Biophytis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Biophytis's sector and industry vertical

Which are the top PE firms investing in Biophytis's sector and industry vertical?

Top PE firms investing in Biophytis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Biophytis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Biophytis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Biophytis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Biophytis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Biophytis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Biophytis?

The key public trading comparables and valuation benchmarks for Biophytis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Biophytis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Biophytis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Biophytis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Biophytis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Biophytis's' sector and industry vertical?

Access recent funding rounds and capital raises in Biophytis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Biophytis